Multidisciplinary Approaches to the Management of Atopic Dermatitis - Episode 11
Future Directions in the Treatment of Pediatric Atopic Dermatitis
Published on:
Panelists discuss when to consider adding or switching agents for atopic dermatitis, highlighting alternative treatments for pediatric patients such as biologics and Janus kinase (JAK) inhibitors, and emphasize the importance of tailoring treatment decisions based on efficacy and patient response, citing studies such as Blauvelt 2023, Keow & Abu-Hilal 2024, and JADE EXTEND. They also explore emerging systemic agents such as nemolizumab (IL-31 receptor antagonist) and rocatinlimab (anti-OX40), which have the potential to significantly affect treatment approaches based on promising early trial results.
Video content above is prompted by the following:
- When do you consider adding or switching agents?
- What other treatment options exist for pediatric atopic dermatitis?
- How do you determine which treatment to switch to?
- Biologic to JAK inhibitor: Blauvelt 2023, Keow & Abu-Hilal 2024, JADE EXTEND, Shi 2022
- Can you discuss some of the systemic agents on the horizon for atopic dermatitis and how they could potentially affect treatment?
a. Nemolizumab (IL-31 receptor antagonist; ARCADIA 1 and ARCADIA 2 ) - Rocatinlimab (anti-OX40): topline results released for one phase 3 study in adults, with adolescent studies still ongoing (press release )
